Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
14hon MSN
Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback